Zentalis Pharmaceuticals, Inc. (ZNTL)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Zentalis Pharmaceuticals, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Zentalis Pharmaceuticals, Inc. (ZNTL) has returned 73.33% so far this year and 47.17% over the past 12 months.

Based on dividend-adjusted daily data since Apr 3, 2020, ZNTL's average daily return is 0.00%, while the average monthly return is -0.30%.

Historically, 42% of months were positive and 58% were negative. The best month was Jan 2026 with a return of +80.0%, while the worst month was Jun 2024 at -65.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.

On a daily basis, ZNTL closed higher 48% of trading days. The best single day was Jan 7, 2026 with a return of +36.0%, while the worst single day was Jun 18, 2024 at -50.7%.

Zentalis Pharmaceuticals, Inc. has an annualized alpha of -24.50%, beta of 1.56, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since April 06, 2020.

• This stock participated in 219.13% of S&P 500 Index downside but only 47.65% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ZNTL ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Zentalis Pharmaceuticals, Inc. (ZNTL) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Zentalis Pharmaceuticals, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Zentalis Pharmaceuticals, Inc. was 98.77%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Zentalis Pharmaceuticals, Inc. drawdown is 97.24%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Zentalis Pharmaceuticals, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Zentalis Pharmaceuticals, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.